ATR vs. CVS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ATR and CVS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
CVS’s market capitalization of 85.30 billion USD is significantly greater than ATR’s 10.64 billion USD, highlighting its more substantial market valuation.
With betas of 0.59 for ATR and 0.56 for CVS, both stocks show similar sensitivity to overall market movements.
| Symbol | ATR | CVS |
|---|---|---|
| Company Name | AptarGroup, Inc. | CVS Health Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Instruments & Supplies | Medical - Healthcare Plans |
| CEO | Stephan B. Tanda | J. David Joyner CEBS |
| Price | 161.04 USD | 67.43 USD |
| Market Cap | 10.64 billion USD | 85.30 billion USD |
| Beta | 0.59 | 0.56 |
| Exchange | NYSE | NYSE |
| IPO Date | April 23, 1993 | November 20, 1996 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ATR and CVS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ATR
14.87%
Medical - Instruments & Supplies Industry
- Max
- 26.65%
- Q3
- 13.00%
- Median
- 1.08%
- Q1
- -8.11%
- Min
- -38.20%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Equity of 14.87% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
CVS
6.98%
Medical - Healthcare Plans Industry
- Max
- 13.94%
- Q3
- 13.62%
- Median
- 11.42%
- Q1
- 7.74%
- Min
- 6.98%
CVS’s Return on Equity of 6.98% is in the lower quartile for the Medical - Healthcare Plans industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Return on Invested Capital
ATR
11.90%
Medical - Instruments & Supplies Industry
- Max
- 20.14%
- Q3
- 7.36%
- Median
- 1.97%
- Q1
- -6.22%
- Min
- -20.00%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Invested Capital of 11.90% signifies a highly effective use of its capital to generate profits when compared to its peers.
CVS
4.03%
Medical - Healthcare Plans Industry
- Max
- 15.50%
- Q3
- 7.12%
- Median
- 5.48%
- Q1
- -3.47%
- Min
- -15.02%
CVS’s Return on Invested Capital of 4.03% is in line with the norm for the Medical - Healthcare Plans industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ATR
10.42%
Medical - Instruments & Supplies Industry
- Max
- 28.95%
- Q3
- 11.24%
- Median
- -2.83%
- Q1
- -12.85%
- Min
- -26.41%
ATR’s Net Profit Margin of 10.42% is aligned with the median group of its peers in the Medical - Instruments & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
CVS
1.39%
Medical - Healthcare Plans Industry
- Max
- 3.23%
- Q3
- 2.62%
- Median
- 1.70%
- Q1
- 1.27%
- Min
- 1.22%
CVS’s Net Profit Margin of 1.39% is aligned with the median group of its peers in the Medical - Healthcare Plans industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ATR
14.17%
Medical - Instruments & Supplies Industry
- Max
- 32.10%
- Q3
- 16.03%
- Median
- 2.28%
- Q1
- -7.96%
- Min
- -26.84%
ATR’s Operating Profit Margin of 14.17% is around the midpoint for the Medical - Instruments & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
CVS
2.54%
Medical - Healthcare Plans Industry
- Max
- 4.30%
- Q3
- 3.77%
- Median
- 2.61%
- Q1
- 1.60%
- Min
- -1.64%
CVS’s Operating Profit Margin of 2.54% is around the midpoint for the Medical - Healthcare Plans industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ATR | CVS |
|---|---|---|
| Return on Equity (TTM) | 14.87% | 6.98% |
| Return on Assets (TTM) | 8.18% | 2.07% |
| Return on Invested Capital (TTM) | 11.90% | 4.03% |
| Net Profit Margin (TTM) | 10.42% | 1.39% |
| Operating Profit Margin (TTM) | 14.17% | 2.54% |
| Gross Profit Margin (TTM) | 36.41% | 14.05% |
Financial Strength
Current Ratio
ATR
1.25
Medical - Instruments & Supplies Industry
- Max
- 6.79
- Q3
- 4.57
- Median
- 2.64
- Q1
- 1.81
- Min
- 1.10
ATR’s Current Ratio of 1.25 falls into the lower quartile for the Medical - Instruments & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
CVS
0.82
Medical - Healthcare Plans Industry
- Max
- 1.91
- Q3
- 1.63
- Median
- 1.43
- Q1
- 0.85
- Min
- 0.78
CVS’s Current Ratio of 0.82 falls into the lower quartile for the Medical - Healthcare Plans industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ATR
0.41
Medical - Instruments & Supplies Industry
- Max
- 1.46
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.16
- Min
- 0.03
ATR’s Debt-to-Equity Ratio of 0.41 is typical for the Medical - Instruments & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CVS
1.06
Medical - Healthcare Plans Industry
- Max
- 1.06
- Q3
- 0.86
- Median
- 0.75
- Q1
- 0.66
- Min
- 0.66
CVS’s leverage is in the upper quartile of the Medical - Healthcare Plans industry, with a Debt-to-Equity Ratio of 1.06. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
ATR
11.17
Medical - Instruments & Supplies Industry
- Max
- 25.04
- Q3
- 8.80
- Median
- 3.66
- Q1
- -3.85
- Min
- -11.93
ATR’s Interest Coverage Ratio of 11.17 is in the upper quartile for the Medical - Instruments & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
CVS
3.18
Medical - Healthcare Plans Industry
- Max
- 6.23
- Q3
- 6.23
- Median
- 5.19
- Q1
- 4.64
- Min
- 3.18
In the lower quartile for the Medical - Healthcare Plans industry, CVS’s Interest Coverage Ratio of 3.18 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | ATR | CVS |
|---|---|---|
| Current Ratio (TTM) | 1.25 | 0.82 |
| Quick Ratio (TTM) | 0.85 | 0.63 |
| Debt-to-Equity Ratio (TTM) | 0.41 | 1.06 |
| Debt-to-Asset Ratio (TTM) | 0.23 | 0.32 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.19 | 4.80 |
| Interest Coverage Ratio (TTM) | 11.17 | 3.18 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ATR and CVS. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ATR
1.12%
Medical - Instruments & Supplies Industry
- Max
- 4.02%
- Q3
- 0.38%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.12%, ATR offers a more attractive income stream than most of its peers in the Medical - Instruments & Supplies industry, signaling a strong commitment to shareholder returns.
CVS
3.94%
Medical - Healthcare Plans Industry
- Max
- 3.88%
- Q3
- 1.78%
- Median
- 0.73%
- Q1
- 0.00%
- Min
- 0.00%
CVS’s Dividend Yield of 3.94% is exceptionally high, placing it well above the typical range for the Medical - Healthcare Plans industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio
ATR
31.58%
Medical - Instruments & Supplies Industry
- Max
- 76.77%
- Q3
- 11.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ATR’s Dividend Payout Ratio of 31.58% is in the upper quartile for the Medical - Instruments & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
CVS
63.88%
Medical - Healthcare Plans Industry
- Max
- 63.88%
- Q3
- 29.91%
- Median
- 12.57%
- Q1
- 0.00%
- Min
- 0.00%
CVS’s Dividend Payout Ratio of 63.88% is in the upper quartile for the Medical - Healthcare Plans industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ATR | CVS |
|---|---|---|
| Dividend Yield (TTM) | 1.12% | 3.94% |
| Dividend Payout Ratio (TTM) | 31.58% | 63.88% |
Valuation
Price-to-Earnings Ratio
ATR
28.83
Medical - Instruments & Supplies Industry
- Max
- 45.65
- Q3
- 44.10
- Median
- 35.47
- Q1
- 29.60
- Min
- 21.65
In the lower quartile for the Medical - Instruments & Supplies industry, ATR’s P/E Ratio of 28.83 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
CVS
16.10
Medical - Healthcare Plans Industry
- Max
- 18.17
- Q3
- 17.32
- Median
- 15.48
- Q1
- 13.55
- Min
- 12.84
CVS’s P/E Ratio of 16.10 is within the middle range for the Medical - Healthcare Plans industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ATR
2.54
Medical - Instruments & Supplies Industry
- Max
- 5.80
- Q3
- 3.68
- Median
- 2.56
- Q1
- 1.87
- Min
- 0.22
ATR’s Forward PEG Ratio of 2.54 is within the middle range of its peers in the Medical - Instruments & Supplies industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
CVS
1.39
Medical - Healthcare Plans Industry
- Max
- 1.41
- Q3
- 1.09
- Median
- 0.85
- Q1
- 0.79
- Min
- 0.60
A Forward PEG Ratio of 1.39 places CVS in the upper quartile for the Medical - Healthcare Plans industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
ATR
2.99
Medical - Instruments & Supplies Industry
- Max
- 12.87
- Q3
- 6.95
- Median
- 3.45
- Q1
- 2.24
- Min
- 0.71
ATR’s P/S Ratio of 2.99 aligns with the market consensus for the Medical - Instruments & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
CVS
0.23
Medical - Healthcare Plans Industry
- Max
- 0.94
- Q3
- 0.64
- Median
- 0.43
- Q1
- 0.27
- Min
- 0.16
In the lower quartile for the Medical - Healthcare Plans industry, CVS’s P/S Ratio of 0.23 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio
ATR
4.18
Medical - Instruments & Supplies Industry
- Max
- 9.60
- Q3
- 5.48
- Median
- 3.37
- Q1
- 1.95
- Min
- 0.65
ATR’s P/B Ratio of 4.18 is within the conventional range for the Medical - Instruments & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
CVS
1.11
Medical - Healthcare Plans Industry
- Max
- 4.08
- Q3
- 3.83
- Median
- 2.63
- Q1
- 1.74
- Min
- 0.96
CVS’s P/B Ratio of 1.11 is in the lower quartile for the Medical - Healthcare Plans industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | ATR | CVS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.83 | 16.10 |
| Forward PEG Ratio (TTM) | 2.54 | 1.39 |
| Price-to-Sales Ratio (P/S, TTM) | 2.99 | 0.23 |
| Price-to-Book Ratio (P/B, TTM) | 4.18 | 1.11 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 29.67 | 14.36 |
| EV-to-EBITDA (TTM) | 14.80 | 10.56 |
| EV-to-Sales (TTM) | 3.25 | 0.41 |